Quick Answer
ICU MEDICAL INC/DE reported R&D Expense of $87.50 million for fiscal year 2025.
ICU MEDICAL INC/DE R&D Expense — Annual History
| Fiscal Year | R&D Expense | YoY Change |
|---|---|---|
| 2025 | $87.50M | -1.3% |
| 2024 | $88.61M | +3.8% |
| 2023 | $85.34M | -8.2% |
| 2022 | $92.98M | +95.8% |
| 2021 | $47.50M | +10.6% |
| 2020 | $42.95M | -11.6% |
| 2019 | $48.61M | -8.1% |
| 2018 | $52.87M | +3.1% |
| 2017 | $51.25M | +295.6% |
| 2016 | $12.96M | -17.6% |
| 2015 | $15.71M | -14.3% |
| 2014 | $18.33M | +47.8% |
| 2013 | $12.41M | +16.7% |
| 2012 | $10.63M | +23.8% |
| 2011 | $8.59M | +83.6% |
| 2010 | $4.68M | +76.9% |
| 2009 | $2.65M | -45.1% |
| 2008 | $4.82M | -40.5% |
| 2007 | $8.11M | — |
Quarterly R&D Expense
| Quarter Ending | R&D Expense | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | $21.25M | +1.1% | -2.8% |
| June 30, 2025 | $21.87M | -6.5% | -6.1% |
| March 31, 2025 | $23.29M | +6.6% | +10.8% |
| September 30, 2024 | $21.03M | +0.8% | -10.1% |
| June 30, 2024 | $23.39M | +4.9% | +7.1% |
| March 31, 2024 | $21.84M | +10.5% | +4.7% |
| September 30, 2023 | $20.87M | -9.7% | -6.4% |
| June 30, 2023 | $22.30M | -1.2% | +12.9% |
- ICU MEDICAL INC/DE showed a decrease of -1.3% in R&D Expense compared to the prior fiscal year.
- Over the 2007–2025 period, ICU MEDICAL INC/DE’s r&d expense has grown by 978.7% (from $8.11 million to $87.50 million).
- The most recent figure is from ICU MEDICAL INC/DE’s fiscal year 2025 report (Form 10-K), filed with the SEC on February 19, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: